What If Alzheimer Does Not Start In Brain
For over a century, scientists have been locked in a singular quest: hunting the roots of Alzheimer’s disease inside the brain. From the sticky amyloid plaques that clog up neurons to the tangled tau proteins and the devastating neuron death that follows, Alzheimer’s has always been labeled a brain disease. But what if this long-held belief is only part of the story—or even completely wrong?
A groundbreaking theory is now shaking the very foundation of Alzheimer’s research. According to a new peer-reviewed study led by researchers at UC San Diego, along with several international collaborators, Alzheimer’s may not begin in the brain at all. Instead, the brain could merely be the final battleground in a war that starts elsewhere—possibly in the liver, kidneys, or bloodstream.
Yes, you read that right. Alzheimer’s might not originate in the brain. And if this theory is correct, it could completely transform how we diagnose, treat, and even think about this devastating condition.
A New Frontier in Alzheimer’s Research
The evidence presented by the researchers is compelling—and disturbing.
First, they found that in up to 70% of Alzheimer’s patients, signs of liver or kidney dysfunction appeared well before any cognitive symptoms showed up. These findings suggest a timeline where something goes wrong in the body long before memory starts to fade.
Second, in a dramatic set of experiments, scientists gave healthy lab animals blood transfusions from human Alzheimer’s patients. The result? The animals started developing changes in their brains that closely resembled early Alzheimer’s pathology. This suggests that toxic agents in the blood—possibly proteins like amyloid or related byproducts—can travel to the brain and trigger neurodegeneration.
Third, researchers discovered that the infamous amyloid plaques associated with Alzheimer’s aren’t confined to the brain. They also show up in the livers, kidneys, and other organs of Alzheimer’s patients, further supporting the idea that the disease could start in the body and spread to the brain.
Why It Matters: A Shift from Brain-Centric Thinking
For decades, researchers and pharmaceutical companies have poured billions into developing drugs to reduce amyloid plaques in the brain. Yet despite hundreds of trials, 99.6% of these treatments have failed. Even lecanemab, a new drug approved in 2023, only slows cognitive decline by a modest 27%. That’s hardly a breakthrough.
This track record has led many to question the so-called “amyloid hypothesis” that has dominated Alzheimer’s science since the 1980s. If we’ve been aiming at the wrong target, it’s no wonder the results have been underwhelming.
The new body-first hypothesis offers a refreshing—if controversial—direction. It suggests that if we want to stop Alzheimer’s before it starts, we may need to think holistically. Instead of just targeting the brain, we might need to focus on improving liver and kidney health, reducing systemic inflammation, and identifying harmful proteins in the blood before they reach the brain.
Imagine a world where a routine blood test in your 50s could predict your Alzheimer’s risk decades in advance. Where interventions like diet, exercise, and liver function support could reduce that risk significantly. That’s the kind of future this research could help unlock.
Too Radical—or Just in Time?
Of course, not everyone is on board. Many neuroscientists who’ve built their careers around brain-centered models of Alzheimer’s view this new approach with skepticism. Some dismiss it outright as “too radical.” But science has a long history of resisting paradigm shifts—until the evidence becomes too powerful to ignore.
In a sense, this could be medicine’s “Copernican moment” for dementia. Just as Copernicus shifted our understanding of the universe by placing the sun, not Earth, at the center, this new theory flips Alzheimer’s on its head. It challenges us to accept that the brain might be a victim—not the villain—in this tragic story.
And here’s a haunting detail to end on: Auguste Deter, the very first Alzheimer’s patient identified by Dr. Alois Alzheimer in 1901, showed signs of liver abnormalities in her medical records. It was a clue buried and forgotten for more than a century.
Maybe it’s time to finally pay attention.